| Azar A Korbey Md,pllc | |
|
22 Main St Salem NH 03079-5900 | |
| (603) 893-7905 | |
| (603) 898-6106 |
| Full Name | Azar A Korbey Md,pllc |
|---|---|
| Speciality | Family Medicine |
| Location | 22 Main St, Salem, New Hampshire |
| Authorized Official Name and Position | Azar Alexander Korbey (OWNER) |
| Authorized Official Contact | 6038937905 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Azar A Korbey Md,pllc 22 Main St Salem NH 03079-5900 Ph: (603) 893-7905 | Azar A Korbey Md,pllc 22 Main St Salem NH 03079-5900 Ph: (603) 893-7905 |
| NPI Number | 1528262680 |
|---|---|
| Provider Enumeration Date | 06/13/2007 |
| Last Update Date | 03/10/2015 |
| Medicare PECOS PAC ID | 0042296592 |
|---|---|
| Medicare Enrollment ID | O20060130000120 |
News Archive
Clarity soft tissue visualization system now provides an Autoscan option for automated ultrasound scanning from outside of the treatment room, employing a motorized probe positioned at the patient's perineum.
Treating a stubborn blood disease that strikes children may come down to tweaking energy production in stem cells, suggests research out of West Virginia University.
Alzheimer's disease has long been studied primarily as a disease of neurons. But researchers have now shown how the disease may be damaging the brain by choking off blood flow. In experiments published June 10 in Neuron, scientists at Rockefeller University reveal that amyloid-β, which builds up around brain cells in Alzheimer's patients, interacts with a common blood clotting agent to increase clotting in the arteries that feed the brain.
Aegerion Pharmaceuticals, Inc. today announced that the underwriters of its October 22, 2010 initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of Aegerion's common stock at $9.50 per share, less underwriting discounts and commissions. The option was granted in connection with Aegerion's initial public offering of 5,000,000 shares. The over-allotment option is expected to close on November 2, 2010, subject to customary closing conditions.
› Verified 4 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528262680 | NPI | - | NPPES |
| 690037 | Other | MA | TUFTS HEALTH PLAN |
| M17685 | Other | MA | BLUE CROSS BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (* (Not Available)) | Primary |
| Provider Name | Theresa L Feldmann |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1457635575 PECOS PAC ID: 3072599521 Enrollment ID: I20040625000904 |
News Archive
Clarity soft tissue visualization system now provides an Autoscan option for automated ultrasound scanning from outside of the treatment room, employing a motorized probe positioned at the patient's perineum.
Treating a stubborn blood disease that strikes children may come down to tweaking energy production in stem cells, suggests research out of West Virginia University.
Alzheimer's disease has long been studied primarily as a disease of neurons. But researchers have now shown how the disease may be damaging the brain by choking off blood flow. In experiments published June 10 in Neuron, scientists at Rockefeller University reveal that amyloid-β, which builds up around brain cells in Alzheimer's patients, interacts with a common blood clotting agent to increase clotting in the arteries that feed the brain.
Aegerion Pharmaceuticals, Inc. today announced that the underwriters of its October 22, 2010 initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of Aegerion's common stock at $9.50 per share, less underwriting discounts and commissions. The option was granted in connection with Aegerion's initial public offering of 5,000,000 shares. The over-allotment option is expected to close on November 2, 2010, subject to customary closing conditions.
› Verified 4 days ago
| Provider Name | Shuwei Liu |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1770563058 PECOS PAC ID: 9133027782 Enrollment ID: I20040908000913 |
News Archive
Clarity soft tissue visualization system now provides an Autoscan option for automated ultrasound scanning from outside of the treatment room, employing a motorized probe positioned at the patient's perineum.
Treating a stubborn blood disease that strikes children may come down to tweaking energy production in stem cells, suggests research out of West Virginia University.
Alzheimer's disease has long been studied primarily as a disease of neurons. But researchers have now shown how the disease may be damaging the brain by choking off blood flow. In experiments published June 10 in Neuron, scientists at Rockefeller University reveal that amyloid-β, which builds up around brain cells in Alzheimer's patients, interacts with a common blood clotting agent to increase clotting in the arteries that feed the brain.
Aegerion Pharmaceuticals, Inc. today announced that the underwriters of its October 22, 2010 initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of Aegerion's common stock at $9.50 per share, less underwriting discounts and commissions. The option was granted in connection with Aegerion's initial public offering of 5,000,000 shares. The over-allotment option is expected to close on November 2, 2010, subject to customary closing conditions.
› Verified 4 days ago
| Provider Name | Azar A Korbey |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1841278058 PECOS PAC ID: 2365486768 Enrollment ID: I20050616000510 |
News Archive
Clarity soft tissue visualization system now provides an Autoscan option for automated ultrasound scanning from outside of the treatment room, employing a motorized probe positioned at the patient's perineum.
Treating a stubborn blood disease that strikes children may come down to tweaking energy production in stem cells, suggests research out of West Virginia University.
Alzheimer's disease has long been studied primarily as a disease of neurons. But researchers have now shown how the disease may be damaging the brain by choking off blood flow. In experiments published June 10 in Neuron, scientists at Rockefeller University reveal that amyloid-β, which builds up around brain cells in Alzheimer's patients, interacts with a common blood clotting agent to increase clotting in the arteries that feed the brain.
Aegerion Pharmaceuticals, Inc. today announced that the underwriters of its October 22, 2010 initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of Aegerion's common stock at $9.50 per share, less underwriting discounts and commissions. The option was granted in connection with Aegerion's initial public offering of 5,000,000 shares. The over-allotment option is expected to close on November 2, 2010, subject to customary closing conditions.
› Verified 4 days ago
| Provider Name | William B Feldmann |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1508821984 PECOS PAC ID: 6901828466 Enrollment ID: I20051227000334 |
News Archive
Clarity soft tissue visualization system now provides an Autoscan option for automated ultrasound scanning from outside of the treatment room, employing a motorized probe positioned at the patient's perineum.
Treating a stubborn blood disease that strikes children may come down to tweaking energy production in stem cells, suggests research out of West Virginia University.
Alzheimer's disease has long been studied primarily as a disease of neurons. But researchers have now shown how the disease may be damaging the brain by choking off blood flow. In experiments published June 10 in Neuron, scientists at Rockefeller University reveal that amyloid-β, which builds up around brain cells in Alzheimer's patients, interacts with a common blood clotting agent to increase clotting in the arteries that feed the brain.
Aegerion Pharmaceuticals, Inc. today announced that the underwriters of its October 22, 2010 initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of Aegerion's common stock at $9.50 per share, less underwriting discounts and commissions. The option was granted in connection with Aegerion's initial public offering of 5,000,000 shares. The over-allotment option is expected to close on November 2, 2010, subject to customary closing conditions.
› Verified 4 days ago
| Provider Name | Rhonda M Hodge |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1801849898 PECOS PAC ID: 5698905602 Enrollment ID: I20140312001592 |
News Archive
Clarity soft tissue visualization system now provides an Autoscan option for automated ultrasound scanning from outside of the treatment room, employing a motorized probe positioned at the patient's perineum.
Treating a stubborn blood disease that strikes children may come down to tweaking energy production in stem cells, suggests research out of West Virginia University.
Alzheimer's disease has long been studied primarily as a disease of neurons. But researchers have now shown how the disease may be damaging the brain by choking off blood flow. In experiments published June 10 in Neuron, scientists at Rockefeller University reveal that amyloid-β, which builds up around brain cells in Alzheimer's patients, interacts with a common blood clotting agent to increase clotting in the arteries that feed the brain.
Aegerion Pharmaceuticals, Inc. today announced that the underwriters of its October 22, 2010 initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of Aegerion's common stock at $9.50 per share, less underwriting discounts and commissions. The option was granted in connection with Aegerion's initial public offering of 5,000,000 shares. The over-allotment option is expected to close on November 2, 2010, subject to customary closing conditions.
› Verified 4 days ago
| Provider Name | Danielle Lemay |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1437665312 PECOS PAC ID: 4688936925 Enrollment ID: I20180326000916 |
News Archive
Clarity soft tissue visualization system now provides an Autoscan option for automated ultrasound scanning from outside of the treatment room, employing a motorized probe positioned at the patient's perineum.
Treating a stubborn blood disease that strikes children may come down to tweaking energy production in stem cells, suggests research out of West Virginia University.
Alzheimer's disease has long been studied primarily as a disease of neurons. But researchers have now shown how the disease may be damaging the brain by choking off blood flow. In experiments published June 10 in Neuron, scientists at Rockefeller University reveal that amyloid-β, which builds up around brain cells in Alzheimer's patients, interacts with a common blood clotting agent to increase clotting in the arteries that feed the brain.
Aegerion Pharmaceuticals, Inc. today announced that the underwriters of its October 22, 2010 initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of Aegerion's common stock at $9.50 per share, less underwriting discounts and commissions. The option was granted in connection with Aegerion's initial public offering of 5,000,000 shares. The over-allotment option is expected to close on November 2, 2010, subject to customary closing conditions.
› Verified 4 days ago
| Provider Name | Samantha Marie Korbey |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1518585421 PECOS PAC ID: 4183043417 Enrollment ID: I20201006000522 |
News Archive
Clarity soft tissue visualization system now provides an Autoscan option for automated ultrasound scanning from outside of the treatment room, employing a motorized probe positioned at the patient's perineum.
Treating a stubborn blood disease that strikes children may come down to tweaking energy production in stem cells, suggests research out of West Virginia University.
Alzheimer's disease has long been studied primarily as a disease of neurons. But researchers have now shown how the disease may be damaging the brain by choking off blood flow. In experiments published June 10 in Neuron, scientists at Rockefeller University reveal that amyloid-β, which builds up around brain cells in Alzheimer's patients, interacts with a common blood clotting agent to increase clotting in the arteries that feed the brain.
Aegerion Pharmaceuticals, Inc. today announced that the underwriters of its October 22, 2010 initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of Aegerion's common stock at $9.50 per share, less underwriting discounts and commissions. The option was granted in connection with Aegerion's initial public offering of 5,000,000 shares. The over-allotment option is expected to close on November 2, 2010, subject to customary closing conditions.
› Verified 4 days ago
News Archive
Clarity soft tissue visualization system now provides an Autoscan option for automated ultrasound scanning from outside of the treatment room, employing a motorized probe positioned at the patient's perineum.
Treating a stubborn blood disease that strikes children may come down to tweaking energy production in stem cells, suggests research out of West Virginia University.
Alzheimer's disease has long been studied primarily as a disease of neurons. But researchers have now shown how the disease may be damaging the brain by choking off blood flow. In experiments published June 10 in Neuron, scientists at Rockefeller University reveal that amyloid-β, which builds up around brain cells in Alzheimer's patients, interacts with a common blood clotting agent to increase clotting in the arteries that feed the brain.
Aegerion Pharmaceuticals, Inc. today announced that the underwriters of its October 22, 2010 initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of Aegerion's common stock at $9.50 per share, less underwriting discounts and commissions. The option was granted in connection with Aegerion's initial public offering of 5,000,000 shares. The over-allotment option is expected to close on November 2, 2010, subject to customary closing conditions.
› Verified 4 days ago
Salem Occupational And Acute Care Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 13 Red Roof Ln Ste 2, Salem, NH 03079 Phone: 603-898-0961 Fax: 603-898-0964 | |
Physician's Diagnostic Services Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 22 Main St, Salem, NH 03079 Phone: 603-898-0961 | |
Claudia Trombly, Md, Pllc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 7 Stiles Rd, Salem, NH 03079 Phone: 603-685-6977 | |
Loew Family Medical Practice, Pllc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 23 Stiles Rd, Suite 213, Salem, NH 03079 Phone: 603-898-9834 Fax: 603-898-8253 | |
Family Health Matters Of Salem Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 23 Stiles Rd, Suite 210, Salem, NH 03079 Phone: 603-890-5585 | |
Speech Therapy Solutions Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 224 Main St Ste 2d, Salem, NH 03079 Phone: 603-893-8550 Fax: 603-893-8680 |